Plain-English answer
Tuberculosis in China is not a solved historical disease. China remains one of the countries contributing the largest share of global TB cases, and control depends on detection, diagnosis, treatment completion, drug-resistance management, public-health reporting, and access for vulnerable groups.
Global context
WHO's 2025 TB reporting estimated that China accounted for 6.5 percent of global TB cases in 2024, one of eight countries that together made up about two-thirds of global cases.
What TB control requires
TB control is a public-health pathway. It begins with symptom recognition, screening in high-risk groups, sputum testing or molecular diagnostics, chest imaging, drug-susceptibility testing, notification, treatment initiation, adherence support, contact investigation, and follow-up. Missing any step can lead to ongoing transmission, relapse, drug resistance, or avoidable death.
China has made substantial progress in TB control over decades, but its population size means even a lower incidence rate can translate into a large number of patients. Migrant workers, older adults, people with diabetes, people living in crowded settings, and people in poorer or remote areas can face higher risk or harder access. Drug-resistant TB adds another layer: longer, more expensive, and more toxic treatment, plus stronger laboratory and case-management requirements.
Why it matters
TB sits between public health and clinical care. Public-health authorities need surveillance, contact tracing, and treatment adherence systems. Hospitals and clinics need diagnostic capacity, infection control, and referral pathways. Insurance and assistance programs matter because delayed diagnosis and interrupted treatment can be driven by cost, travel, and work disruption.
TB also intersects with chronic disease. Diabetes increases TB risk and can complicate treatment. Aging changes susceptibility and presentation. Urban migration can make continuity difficult when people move between registration, work, and treatment locations. This is why TB pages should not simply describe a bacterium; they should explain the program needed to interrupt transmission.
Control-program caution
TB burden should be judged by the full cascade: diagnosis, notification, drug-susceptibility testing, treatment initiation, adherence, completion, and contact management.
How to read the pathway
Find missing cases
Undetected TB sustains transmission and delays care.
Check resistance
Rifampicin resistance and multidrug resistance change cost, duration, and clinical risk.
Support completion
TB treatment requires months of adherence and practical support.
Strategic meaning
For strategy, TB creates demand for diagnostics, molecular testing, digital adherence support, public-health information systems, infection-control tools, and integrated care for diabetes and TB. The buyer may be a public-health program, hospital laboratory, CDC system, local government, or donor-supported initiative. The key is whether the tool improves the program cascade rather than simply adding another test.
Research anchors
| Source | What it adds | How to use it |
|---|---|---|
| WHO Global Tuberculosis Report 2025 incidence section | Places China in the global TB burden for 2024. | Use it for current global context. |
| WHO Global Tuberculosis Report 2024 | Provides TB burden, diagnosis, treatment, and program reporting framework. | Use it for TB cascade concepts. |
| Frontiers TB burden in China study | Analyzes China's TB burden trends from 1990 to 2021. | Use it for historical trend analysis. |